Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

West Nile Immune Globulin - OMRIX

Drug Profile

West Nile Immune Globulin - OMRIX

Alternative Names: Omr-IgG-am™-WNIG; WNIG

Latest Information Update: 07 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - West Nile virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued West Nile virus infections

Most Recent Events

  • 07 Sep 2015 Discontinued - Phase-II for West Nile virus infections in USA (IV)
  • 16 Aug 2010 Phase-II clinical trials in West Nile virus infections in USA (IV)
  • 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top